Kazia Therapeutics Announces Executive Changes
Company Announcements

Kazia Therapeutics Announces Executive Changes

Kazia Therapeutics (KZIA) has released an update.

Kazia Therapeutics announces organizational changes with the resignation of Gabrielle Heaton, Vice President of Finance and Administration, effective June 28, 2024, which is not due to any internal disagreements. Jeffrey Bonacorda has been appointed as the new Principal Accounting Officer and Principal Financial Officer starting July 1, 2024, bringing over 25 years of experience in various industries. Bonacorda’s appointment is part of the company’s strategic alignment and his annual salary will be $150,000.

For further insights into KZIA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskKazia Therapeutics Advances Paxalisib with FDA Meeting
TheFlyKazia Therapeutics announces granting of Type C meeting with FDA
Sheryl ShethUpcoming Stock Splits This Week (October 28 to November 1) – Stay Invested
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App